Ameriprise
RNAC icon

Ameriprise’s Cartesian Therapeutics RNAC Stock Holding History

Ameriprise’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.5K Sell
13,416
-6,390
-32% -$45.5K ﹤0.01% 3977
2025
Q4 		$143K Buy
+19,806
New +$160K ﹤0.01% 3968
2024
Q1 		– Sell
-11,716
Closed -$242K – 3943
2023
Q4 		$242K Sell
11,716
-1,782
-13% -$53.2K ﹤0.01% 3671
2023
Q3 		$429K Sell
13,498
-120
-0.9% -$4.01K ﹤0.01% 3467
2023
Q2 		$458K Buy
13,618
+657
+5% +$23.5K ﹤0.01% 3473
2023
Q1 		$540K Buy
12,961
+3,673
+40% +$173K ﹤0.01% 3402
2022
Q4 		$316K Sell
9,288
-182
-2% -$7.74K ﹤0.01% 3567
2022
Q3 		$466K Sell
9,470
-290
-3% -$15.9K ﹤0.01% 3419
2022
Q2 		$383K Sell
9,760
-4,038
-29% -$120K ﹤0.01% 3484
2022
Q1 		$509K Buy
13,798
+4,101
+42% +$257K ﹤0.01% 3481
2021
Q4 		$949K Buy
+9,697
New +$1.04M ﹤0.01% 3283
2021
Q3 		– Sell
-1,372
Closed -$172K – 3943
2021
Q2 		$172K Sell
1,372
-1,511
-52% -$180K ﹤0.01% 3776
2021
Q1 		$391K Sell
2,883
-143
-5% -$17.8K ﹤0.01% 3491
2020
Q4 		$275K Buy
3,026
+1,559
+106% +$135K ﹤0.01% 3526
2020
Q3 		$109K Sell
1,467
-133
-8% -$10.2K ﹤0.01% 3633
2020
Q2 		$136K Buy
+1,600
New +$145K ﹤0.01% 3554
2018
Q4 		– Sell
-4,502
Closed -$2.1M – 3752
2018
Q3 		$2.1M Buy
4,502
+1,722
+62% +$692K ﹤0.01% 2800
2018
Q2 		$1.1M Buy
+2,780
New +$986K ﹤0.01% 2979

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's RNAC Position: Q1 2026 in Review

Ameriprise reduced its Cartesian Therapeutics (RNAC) stake by 32% in Q1 2026, selling an estimated $45.5K and leaving 13,416 shares worth $82.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3977.

Ameriprise first reported a position in RNAC in Q2 2018 and has held it in 18 quarters since. The position peaked at $2.1M in Q3 2018. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Ameriprise held 13,416 shares of Cartesian Therapeutics worth $82.5K as of Q1 2026.
  • Ameriprise sold 6,390 Cartesian Therapeutics shares in Q1 2026, an estimated $45.5K.
  • Cartesian Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3977 holding.
  • Ameriprise first reported a position in Cartesian Therapeutics in Q2 2018 and has held it in 18 quarters since.
  • Ameriprise's Cartesian Therapeutics position peaked at $2.1M in Q3 2018.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.